Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BNT 221

Next Previous
Search
Drug Profile

BNT 221

Alternative Names: BNT-221; NEO-PTC-01

Latest Information Update: 18 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Neon Therapeutics
  • Developer BioNTech
  • Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Malignant melanoma
  • Discontinued Solid tumours

Most Recent Events

  • 18 Apr 2025 Discontinued - Preclinical for Solid tumours in USA (Parenteral) (BioNTech pipeline; April 2025)
  • 18 Apr 2025 BioNTech terminates the Phase-I clinical trials in Malignant melanoma (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy, Combination therapy, Second-line therapy or greater) in Belgium, Netherlands(IV) due to sponsor decision (NCT04625205)
  • 05 Apr 2024 Phase I clinical development in Malignant melanoma (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) is ongoing in Netherlands (IV) (NCT04625205)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top